- Case report
- Open Access
- Open Peer Review
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
© Milosevic et al.; licensee BioMed Central. 2014
- Received: 7 December 2013
- Accepted: 11 December 2014
- Published: 17 December 2014
Serious thromboembolic events connected with rFVIIa therapy in hemophilia patients are rare. Only three cases are reported in children, all of them with hemophilia A.
We present unique case of patient with hemophilia B and high titer inhibitors to coagulation FIX, who developed severe renal damage due to thromboembolic event during rFVIIa therapy, associated with unsuspected renovascular anomalies.
Caution is necessary if hematuria B requires administration of rFVIIa. US color doppler renal imaging before and after drug administration should be sufficient as an early warning.
- Vascular Anomaly
- Hemophilia Patient
- rFVIIa Administration
- Multiple Renal Artery
Recombinant factor VIIa (rFVIIa, Novoseven®) has been shown to induce hemostasis in hemophilia patients with inhibitors against factor VIII or factor IX independent of factor VIII/factor IX. rFVIIa initiates hemostasis by forming a complex with tissue factor (TF) exposed as a result of vessel wall injury. Pharmacologic doses of rFVIIa can enhance thrombin generation. Recombinant activated factor VII (rFVIIa, Novoseven®) is in regular clinical use in haemophilia B patients with high-titer inhibitors to coagulation factor IX (FIX) since 1996 . Potential adverse event of rFVIIa therapy is pathological blood clotting. However, when rFVIIa is used in labeled indications such adverse event is rare and did not appear to be dose-related. The incidence of serious thromboembolic events after treatment with rFVIIa in hemophilia patients with inhibitors appears to be much less than 1%, with only three cases reported in children, all of them with hemophilia A and predisposing factors -.
We present the patient with hemophilia B and high titer inhibitors to coagulation FIX who was treated with rFVIIa for severe life-threatening hematuria. Although hematuria was successfully treated, renal thromboembolic adverse event associated with unsuspected vascular anomalies resulted in severe renal damage. To our knowledge, this is the first case of tromboembolic event connected with rFVIIa therapy with this set of symptoms presented exclusively on kidney with underlying vascular anomalies. The second normal kidney was fully spared.
The risk of clot formation is low even if rFVIIa was given in higher doses (>300 mcg/kg BW) ,. But the treatment with high doses of rFVIIa on an off-label basis significantly increases the risk of arterial but not venous thromboembolic events among the elderly . In the literature we found a report of a woman with Glanzmann Thrombasthenia with haematuria and clotting in renal pelvis after rFVIIa administration. In this case, the major reason for rFVIIa administration was intraoperative bleeding, during laparotomy for pelvic inflammatory disease. It is well known that inflammatory process activate "kinin-kallikrein" system and that leads to increased clotting .
Our patient had multiple renal vascular anomalies. Multiple renal arteries are not uncommon. Various reports estimate its incidence up to 32%, usually on the right side with very rare occurrence of triple arteries supplying one kidney -. Anatomical variations of multiple renal veins are less common with incidence ranging between 0.8 and 6% . Both anomalies occur far more commonly on the right side ,,. Anomalies occurring in both arteries and vein together are extremely rare. To our knowledge, this is the first report of combination of both multiple arterial and vein kidney anomalies of one kidney while the other kidney had normal circulatory system. As we did not exceed recommended rFVIIa dosage and as right kidney was spared, the contribution of such vascular anomaly to the thromboembolic incident of the left kidney is a reasonable assumption. According to radionuclide examinations the main site of lesion and clotting event was intrarenal vascular bed, primarily in glomerular region, while tubular region was less affected. Renal damage secondary to pelvicaliceal obstruction is less likely.
Such an extremely rare troboembolic event in patients with hemophilia B certainly do not compromise safe administration of rFVIIa. However, caution is necessary if hematuria requires administration of rFVIIa. US color doppler renal imaging before and after drug administration should be sufficient as an early warning.
Written informed consent was obtained from the patient’s parents for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
We have no people to match to acknowledgements criteria.
- Astermark J: Treatment of the bleeding inhibitor patient. Semin Thromb Hemost. 2003, 29: 77-85. 10.1055/s-2003-37972.View ArticlePubMedGoogle Scholar
- Abshire T, Kenet G: Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemostasis. 2004, 2: 899-909. 10.1111/j.1538-7836.2004.00759.x.View ArticleGoogle Scholar
- Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14(5):898-902.Google Scholar
- Chuansumrit A, Angchaisuksiri P, Sirachainan N: Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors. J Blood Med. 2010, 1: 37-48. 10.2147/JBM.S6209.View ArticlePubMedPubMed CentralGoogle Scholar
- Salaj P, Brabec P, Penka M, Salaj P, Brabec P, Penka M, Pohlreichova V, Smejkal P, Cetkovsky P, Dusek L, Hedner U: Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors:analysis of HemoRec registry data from the Czech Republic. Haemophilia. 2009, 15: 752-759. 10.1111/j.1365-2516.2009.02007.x.View ArticlePubMedGoogle Scholar
- Young G, Cooper DL, Gut RZ: Dosing and effectivness of recombinant activated factor VII (rFVIIa) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004–2008). Haemaophilia. 2012, 18: 990-996. 10.1111/j.1365-2516.2012.02864.x.View ArticleGoogle Scholar
- Levi M, Levy JH, Andersen HF, Truloff D: Safety of Recombinant Activated Factor VII in Randomised Clinical Trials. N Engl J Med. 2010, 363: 1791-1800. 10.1056/NEJMoa1006221.View ArticlePubMedGoogle Scholar
- Robinson KL, Savoia H, Street AM: Thrombotic complications in two patients receiving NovoSeven. Haemophilia. 2000, 6: 349-Google Scholar
- Harrison LH, Flye MW, Seigler HF. Incidence of anatomical variants in renal vasculature in the presence of normal renal function. Ann Surg 1978; 188(1):83-9.Google Scholar
- Mir NS, ul Hassan A, Rangrez R, Hamid S, Sabia, Tabish SA, Iqbal, Suhalia, Massarat, Rasool Z. Bilateral duplication of renal vessels: anatomical, medical and surgical perspective. Int J Health Sci (Qassim) 2008; 2:179–185.Google Scholar
- Das S: Anomalous renal arteries and its clinical imp'lications. Bratisl Lek Listy. 2008, 109: 182-184.PubMedGoogle Scholar
- Satyapal KS, Haffjee AA, Singh B, Ramsaroop L, Robbs JV, Kalideen JM: Additional renal arteries incidence and morphometry. Surg Radiol Anat. 2001, 23: 33-38. 10.1007/s00276-001-0033-y.View ArticlePubMedGoogle Scholar
- Chavan SK, Wabale NR, Daimi RS: Unusual variation of the renal vessels-a case report. Pravara Med Rev. 2010, 2 (3): 32-34.Google Scholar
- Fernandes RMP, Conte FHP, Favorito LA, Abidu-Figueiredo M, Babinski MA: Triple right renal vein: an uncommon variation. Int J Morphol. 2005, 23: 231-233. 10.4067/S0717-95022005000300007.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.